Vpr
Vpr
批准号:
8705387
负责人:
YONG-HUI ZHENG
金额:
$19.19万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-01 至 2017-07-31
关键词:
Anti-Retroviral AgentsArsenic TrioxideBinding ProteinsBiological ModelsBiologyCD4 Positive T LymphocytesCXCR4 geneCell Cycle ArrestCell LineCellsDevelopmentDisease ProgressionDrug TargetingG2 PhaseGenesHIV-1HIV-2HumanInfectionIntegration Host FactorsLeadLife Cycle StagesMass Spectrum AnalysisMyeloid CellsOutcomePathway interactionsPlayPrimate LentivirusesPublic HealthReportingResearchResistanceRoleSIVTestingTranslatingUbiquitinViralVirionVirusVirus Replicationantiretroviral therapyin vitro activityin vivoinhibitor/antagonistinnovationlymphoblastoid cell linemacrophagemonocytemulticatalytic endopeptidase complexnef Proteinnovelparalogous genepublic health relevancetoolvif Genesvpr Gene Products
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Vpr and vpx are two viral accessory genes that are expressed in primate lentiviruses, which are required for viral replication and disease progression in vivo. Vpr has two well-known activities in vitro: arrest of cell cycle in G2 phase and enhancement of viral replication in monocyte-derived macrophages. Sharing ~25% homology with Vpr, Vpx only has the viral enhancement activity. Although both Vpr and Vpx enhance HIV-1 replication, different mechanisms are involved. While Vpx counteracts the antiretroviral activity of SAMHD1, the mechanism of Vpr enhancement of viral replication is still unknown. Recently, we reported a potent HIV-1 restriction in the human CD4+ T cell line CEM.NKR (NKR), which was naturally isolated from the human T lymphoblastoid cell line CEM. Although NKR cells express both CD4 and CXCR4, HIV-1 replication is severely restricted from the 2nd round of replication. From the original NKR cells, we isolated three types of clones that show different levels of HIV-1 resistance: non-permissive (NP), semi-permissive (SP), and permissive (P). We then compared wild-type (WT) and Vpr-deficient ( Vpr) HIV-1 replication in these cells. In non-permissive cells, both WT and Vpr viruses were unable to replicate. Notably, a treatment with arsenic trioxide (As2O3) increased the WT virus replication by almost 1000-fold, but did not promote the Vpr virus replication. Similarly, although the WT virus could replicate in the semi-permissive and permissive cells, the Vpr virus replication was completely inhibited in the semi-permissive cells and significantly delayed in the permissive cells. These results suggest that Vpr is absolutely required for HIV-1 replication in the non-permissive and semi-permissive cells. Thus, we have identified Vpr-specific HIV-1 non-permissive human CD4+ T cell line, which represents an important progress in the Vpr field. Our objective is to decipher the mechanism of how Vpr enhances HIV-1 replication in NKR cells. Our hypothesis is that NKR cells may express a Vpr-sensitive restriction factor to block viral replication, or lack a Vpr-like
positive factor to support viral replication. Our rationale is that these NKR cells provide a relevant model system for studying Vpr function, which will be useful for further characterization of Vpr activity in vivo. We propose three specific aims: 1) Delineate how Vpr enhances HIV-1 replication in NKR cells; 2) Identify the host factor in NKR cells that is responsible for Vpr- dependent HIV-1 replication; 3) Elucidate the relevance of HIV-1 restriction in NKR cells for HIV-1 biology. We will define the enigmatic role of Vpr in viral life cycle. The discovered new mechanism will be likely translated into innovative tools for antiretroviral therapy.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.3390/v7102869
发表时间:
2015-09-29
期刊:
Viruses
影响因子:
--
作者:
[Gupta A, Brown CT, Zheng YH, Adami C]
通讯作者:
Adami C
HIV-1 Env gp160 maturation in the Golgi apparatus
-
批准号:10626272
-
项目类别:
-
资助金额:$39.98万
-
财政年份:2023
-
负责人:YONG-HUI ZHENG
-
依托单位:
The role of SERINC5 in HIV-1 replication
-
批准号:10817137
-
项目类别:
-
资助金额:$39.12万
-
财政年份:2019
-
负责人:YONG-HUI ZHENG
-
依托单位:
The role of SERINC5 in HIV-1 replication
-
批准号:9974474
-
项目类别:
-
资助金额:$39.13万
-
财政年份:2019
-
负责人:YONG-HUI ZHENG
-
依托单位:
The role of SERINC5 in HIV-1 replication
-
批准号:10792073
-
项目类别:
-
资助金额:$34.12万
-
财政年份:2019
-
负责人:YONG-HUI ZHENG
-
依托单位:
Mechanism of HIV-1 Env Degradation by the ERAD pathway
-
批准号:9324121
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2016
-
负责人:YONG-HUI ZHENG
-
依托单位:
To eradicate the HIV macrophage reservoir
-
批准号:8972781
-
项目类别:
-
资助金额:$19.97万
-
财政年份:2015
-
负责人:YONG-HUI ZHENG
-
依托单位:
Vpr
-
批准号:8602711
-
项目类别:
-
资助金额:$21.64万
-
财政年份:2013
-
负责人:YONG-HUI ZHENG
-
依托单位:
Actions of Vif and APOBEC3 proteins in HIV-1 Replication
-
批准号:8138198
-
项目类别:
-
资助金额:$16.09万
-
财政年份:2010
-
负责人:YONG-HUI ZHENG
-
依托单位:
Mechanism of APOBEC3-Mediated Innate Immunity to HIV-1
-
批准号:8114377
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2010
-
负责人:YONG-HUI ZHENG
-
依托单位:
Mechanism of APOBEC3-Mediated Innate Immunity to HIV-1
-
批准号:7919755
-
项目类别:
-
资助金额:$4.9万
-
财政年份:2009
-
负责人:YONG-HUI ZHENG
-
依托单位:
Actions of Vif and APOBEC3 proteins in HIV-1 Replication
-
批准号:7919639
-
项目类别:
-
资助金额:$14.61万
-
财政年份:2009
-
负责人:YONG-HUI ZHENG
-
依托单位:
Mechanism of APOBEC3-Mediated Innate Immunity to HIV-1
-
批准号:8096732
-
项目类别:
-
资助金额:$10.38万
-
财政年份:2008
-
负责人:YONG-HUI ZHENG
-
依托单位:
Mechanism of APOBEC3-Mediated Innate Immunity to HIV-1
-
批准号:7646462
-
项目类别:
-
资助金额:$10.38万
-
财政年份:2008
-
负责人:YONG-HUI ZHENG
-
依托单位:
Mechanism of APOBEC3-Mediated Innate Immunity to HIV-1
-
批准号:8304277
-
项目类别:
-
资助金额:$10.38万
-
财政年份:2008
-
负责人:YONG-HUI ZHENG
-
依托单位:
Mechanism of APOBEC3-Mediated Innate Immunity to HIV-1
-
批准号:7555105
-
项目类别:
-
资助金额:$10.38万
-
财政年份:2008
-
负责人:YONG-HUI ZHENG
-
依托单位:
Mechanism of APOBEC3-Mediated Innate Immunity to HIV-1
-
批准号:7888199
-
项目类别:
-
资助金额:$10.38万
-
财政年份:2008
-
负责人:YONG-HUI ZHENG
-
依托单位:
Actions of Vif and APOBEC3 proteins in HIV-1 Replication
-
批准号:7610889
-
项目类别:
-
资助金额:$32.36万
-
财政年份:2006
-
负责人:YONG-HUI ZHENG
-
依托单位:
Actions of Vif and APOBEC3 proteins in HIV-1 Replication
-
批准号:7167467
-
项目类别:
-
资助金额:$33.36万
-
财政年份:2006
-
负责人:YONG-HUI ZHENG
-
依托单位:
Actions of Vif and APOBEC3 proteins in HIV-1 Replication
-
批准号:7414114
-
项目类别:
-
资助金额:$32.36万
-
财政年份:2006
-
负责人:YONG-HUI ZHENG
-
依托单位:
Actions of Vif and APOBEC3 Proteins in HIV-1 Replication
-
批准号:8329145
-
项目类别:
-
资助金额:$36.18万
-
财政年份:2006
-
负责人:YONG-HUI ZHENG
-
依托单位:
海外基金